Edition:
India

Dicerna Pharmaceuticals Inc (DRNA.OQ)

DRNA.OQ on NASDAQ Stock Exchange Global Select Market

12.60USD
20 Jun 2018
Change (% chg)

$0.07 (+0.56%)
Prev Close
$12.53
Open
$12.62
Day's High
$12.77
Day's Low
$12.22
Volume
216,827
Avg. Vol
147,707
52-wk High
$15.80
52-wk Low
$2.69

Select another date:

Thu, May 17 2018

BRIEF-Dicerna Pharmaceuticals Files For Mixed Shelf Of Upto $250 Mln - SEC Filing

* DICERNA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $250 MILLION - SEC FILING Source text: (https://bit.ly/2rQEqC9) Further company coverage:

U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

UPDATE 2-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

CORRECTED-UPDATE 1-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Dicerna Pharmaceuticals Inc on Friday said that it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

CORRECTED-Biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Dicerna Pharmaceuticals Inc on Friday said it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

BRIEF-Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals

* ALNYLAM REACHES SETTLEMENT AGREEMENT WITH DICERNA PHARMACEUTICALS RESOLVING TRADE SECRET MISAPPROPRIATION AND OTHER PENDING LITIGATION

BRIEF-Dicerna Pharma Files ‍Prospectus Related To Offering

* DICERNA PHARMACEUTICALS INC FILES ‍PROSPECTUS RELATED TO OFFERING UP TO 24.5 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING​ Source text: (http://bit.ly/2FKmcfn) Further company coverage:

BRIEF-Dicerna Reports Qtrly Loss Per Share Of $0.90

* DICERNA REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL AND OPERATING RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Ecor1 Capital Llc Reports a 9.4 Percent Passive Stake In Dicerna Pharmaceuticals

* ECOR1 CAPITAL, LLC REPORTS A 9.4 PERCENT PASSIVE STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 20, 2017 Source text: (http://bit.ly/2Ac7p5t) Further company coverage:

Select another date: